Physician profile
Jan Burger
NPI 1003901612
$33,110.13
in general payments reported to CMS, 2019-2025
20 companies · $3,812 in 2025
The $3,812 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.06 · 2020: $5,380 · 2021: $2,749 · 2022: $15K · 2023: $3,733 · 2024: $2,021 · 2025: $3,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,910 · Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,910.00 |
| Food and Beverage | $656.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $10,000.91 | 2020-2025 | Imbruvica |
| Janssen Global Services, LLC | $9,856.19 | 2020-2025 | Imbruvica |
| Pharmacyclics LLC, An Abbvie Company | $5,792.43 | 2021-2022 | |
| Csl Behring | $2,731.25 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $2,155.24 | 2022-2024 | |
| Beigene USA, INC. | $1,980.07 | 2022-2024 | Brukinsa |
| Genentech, INC. | $150.00 | 2022 | |
| Sobi, INC | $120.73 | 2024-2025 | |
| Abbvie INC. | $120.63 | 2024-2025 | |
| Beone Medicines USA, INC. | $120.38 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $24.06 | 2019 | |
| Astellas Pharma US INC | $20.90 | 2023 | Xospata |
| Otsuka America Pharmaceutical, INC. | $20.20 | 2025 | Rexulti |
| Azurity Pharmaceuticals, INC. | $17.14 | 2025 | Danziten |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Burger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.